In Q3 FY2026 ended March 31, 2026, Rezolute reported no revenue and a net loss of $16.2 million, a 14.5% increase from the prior year. Operating loss was $17.4 million, up 13.3% year-over-year. Diluted EPS was -$0.16, compared to -$0.27 a year ago. The company held $11.2 million in cash and $116.8 million in equity, with no long-term debt.
•Net loss widened 14.5% to $16.2 million.
•Operating loss increased 13.3% to $17.4 million.
•Diluted EPS improved to -$0.16 from -$0.27.
•Cash and equivalents totaled $11.2 million; no long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder
For the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. Founded in 2010 and headquartered in Redwood City, California, Rezolute was formerly known as AntriaBio, Inc. before rebranding in December 2017.
Rezolute, Inc. is a late-stage rare disease company focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody. Ersodetug is currently in Phase 3 clinical trials for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia associated with tumor hyperinsulinism. The company was founded in 2010 and is headquartered in Redwood City, California. It was formerly known as AntriaBio, Inc. before rebranding in December 2017.
On which stock exchange is Rezolute listed and what is its currency?
Rezolute, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol RZLT. The company trades in U.S. dollars (USD), which is the currency of its home country, the United States. As a Nasdaq-listed company, it is subject to the reporting and governance standards of that exchange.
What sector and industry does Rezolute operate in?
Rezolute operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing therapies for rare diseases, particularly those involving hypoglycemia caused by hyperinsulinism. Its work involves monoclonal antibody technology, with its lead candidate ersodetug targeting congenital hyperinsulinism and tumor hyperinsulinism. The company's efforts are centered on late-stage clinical development, aiming to bring treatments to patients with significant unmet medical needs.
Where is Rezolute headquartered and what markets does it serve?
Rezolute is headquartered in Redwood City, California, United States. The company primarily serves the U.S. market, as indicated by its focus on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its clinical programs are directed at addressing rare diseases within the country, though its research and development efforts may have broader implications. The company's geographic focus is domestic, with its operations and clinical trials centered in the U.S.
What is Rezolute's lead product candidate and what conditions does it target?
Rezolute's lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody. It is being developed for the treatment of hypoglycemia caused by hyperinsulinism. Specifically, ersodetug is in Phase 3 clinical trials for congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, and for hypoglycemia associated with tumor hyperinsulinism. Congenital hyperinsulinism leads to persistently low blood sugar in infants and children, while tumor hyperinsulinism involves insulin-secreting tumors. Ersodetug aims to address these conditions by targeting the underlying mechanism of excess insulin.